期刊文献+
共找到96,997篇文章
< 1 2 250 >
每页显示 20 50 100
Collision carcinoma of squamous cell carcinoma and small cell neuroendocrine carcinoma of the larynx:A case report and review of the literature 预览
1
作者 Qi Yu Ya-Lian Chen +5 位作者 Shui-Hong Zhou Zhe Chen Yang-Yang Bao Han-Jin Yang Hong-Tian Yao Ling-Xiang Ruan 《世界临床病例杂志》 2019年第2期242-251,共10页
BACKGROUND Collision carcinoma is rare in clinical practice,especially in the head and neck region.In this paper,we report a case of squamous cell carcinoma(SCC)and neuroendocrine carcinoma(NEC)colliding in the larynx... BACKGROUND Collision carcinoma is rare in clinical practice,especially in the head and neck region.In this paper,we report a case of squamous cell carcinoma(SCC)and neuroendocrine carcinoma(NEC)colliding in the larynx and review 12 cases of collision carcinoma in the head and neck to further understand collision carcinoma,including its definition,diagnosis,and treatment.CASE SUMMARY A 61-year-old man presented with a 1-year history of hoarseness.Contrastenhanced magnetic resonance imaging of the larynx revealed that the right vocal cord had a nodule-like thickening with obvious enhancement.Laryngoscopy revealed a neoplasm on the right vocal cord,and a malignant tumor was initially considered.A frozen section of right vocal cord was performed under general anesthesia.The pathological result showed a malignant tumor in the right vocal cord.The tumor was excised with a CO2 laser(Vc type).Routine postoperative pathology showed moderately differentiated SCC with small cell NEC in the right vocal cord.No metastatic lymph nodes or distant metastases were found on postoperative positron emission tomography/computed tomography.Because of the coexistence of SCC and NEC,the patient received adjuvant chemotherapy and radiotherapy.The patient was followed for 8 mo,and no recurrence or distant metastasis was found.CONCLUSION The treatment of collision carcinoma in the head and neck region is uncertain due to the small number of cases. 展开更多
关键词 COLLISION CARCINOMA NEUROENDOCRINE CARCINOMA SQUAMOUS cell CARCINOMA Head and NECK LARYNX Case report
在线阅读 免费下载
Porphyromonas gingivalis and digestive system cancers 预览
2
作者 Ying Zhou Guang-Hua Luo 《世界临床病例杂志》 2019年第7期819-829,共11页
Porphyromonas gingivalis (P. gingivalis) is an anaerobic gram-negative bacterium that colonizes in the epithelium and has been strongly associated with periodontal disease. Recently, various degrees of associations be... Porphyromonas gingivalis (P. gingivalis) is an anaerobic gram-negative bacterium that colonizes in the epithelium and has been strongly associated with periodontal disease. Recently, various degrees of associations between P. gingivalis and digestive system cancers, including oral squamous cell carcinoma in the oral cavity, oesophageal squamous carcinoma in the digestive tract, and pancreatic cancer in pancreatic tissues, have been displayed in multiple clinical and experimental studies. Since P. gingivalis has a strong association with periodontal diseases, not only the relationships between P. gingivalis and digestive system tumours but also the effects induced by periodontal diseases on cancers are well-illustrated in this review. In addition, the prevention and possible treatments for these digestive system tumours induced by P. gingivalis infection are also included in this review. At the end, we also highlighted the possible mechanisms of cancers caused by P. gingivalis. One important carcinogenic effect of P. gingivalis is inhibiting the apoptosis of epithelial cells, which also plays an intrinsic role in protecting cancerous cells. Some signalling pathways activated by P. gingivalis are involved in cell apoptosis, tumourigenesis, immune evasion and cell invasion of tumour cells. In addition, metabolism of potentially carcinogenic substances caused by P. gingivalis is also one of the connections between this bacterium and cancers. 展开更多
关键词 PORPHYROMONAS gingivalis Oral SQUAMOUS CELL CARCINOMA OESOPHAGEAL SQUAMOUS CELL CARCINOMA Pancreatic cancer Periodontal diseases
在线阅读 免费下载
Gut-associated lymphoid tissue or so-called “dome” carcinoma of the colon: Review 预览
3
作者 Aoife J McCarthy Runjan Chetty 《世界胃肠肿瘤学杂志:英文版(电子版)》 CAS 2019年第1期59-70,共12页
AIM To present a comprehensive review of the etiology, clinical features, macroscopic and pathological findings, and clinical significance of Gut-associated lymphoid tissue or “dome” carcinoma of the colon. METHODS ... AIM To present a comprehensive review of the etiology, clinical features, macroscopic and pathological findings, and clinical significance of Gut-associated lymphoid tissue or “dome” carcinoma of the colon. METHODS The English language medical literature on gut- or gastrointestinal-associated lymphoid tissue (GALT) or “dome” carcinoma of the colon was searched and appraised. RESULTS GALT/dome-type carcinomas of the colon are thought to arise from the M-cells of the lymphoglandular complex of the intestine. They are typically asymptomatic and have a characteristic endoscopic plaque-or “dome”-like appearance. Although the histology of GALT/dome-type carcinomas displays some variability, they are characterized by submucosal localization, a prominent lymphoid infiltrate with germinal center formation, tumor-infiltrating lymphocytes, absence of desmoplasia, and dilated glands lined by columnar epithelial cells with bland nuclear features and cytoplasmic eosinophilia. None of the patients reported in the literature with follow-up have developed metastatic disease or local recurrence. CONCLUSION Increased awareness amongst histopathologists of this variant of colorectal adenocarcinoma is likely to lead to the recognition of more cases. 展开更多
关键词 Dome-type CARCINOMA Gastrointestinal-associated LYMPHOID TISSUE CARCINOMA Gut-associated LYMPHOID TISSUE Lymphoglandular complex Colorectal cancer
在线阅读 免费下载
AKR1B10抑制剂增强索拉非尼对小鼠肝癌异种移植瘤的抑制作用
4
作者 金圆圆 韩超 +9 位作者 耿楠 李昱蓉 郑乐育 朱维佳 李艳伟 安子英 赵连荣 王静艳 窦晓光 白菡 《中华肝脏病杂志》 CAS CSCD 北大核心 2019年第1期39-44,共6页
目的探讨AKR1B10抑制剂联合索拉非尼对小鼠肝癌异种移植瘤生长的抑制作用。方法建立裸鼠HepG2肝癌细胞异种移植瘤模型,随机分为4组:对照组、依帕司他单药组、索拉非尼单药组、联合治疗组;比较各组瘤体体积、瘤体质量、给病组和对照组瘤... 目的探讨AKR1B10抑制剂联合索拉非尼对小鼠肝癌异种移植瘤生长的抑制作用。方法建立裸鼠HepG2肝癌细胞异种移植瘤模型,随机分为4组:对照组、依帕司他单药组、索拉非尼单药组、联合治疗组;比较各组瘤体体积、瘤体质量、给病组和对照组瘤体平均质量比值、裸鼠体质量变化情况评价疗效,免疫组织化学法检测瘤体组织中Ki-67的表达评估肿瘤细胞增殖情况。多组间比较采用单因素方差分析,两样本均数用t检验,多样本率用χ^2检验。结果治疗前后移植瘤体积差值在对照组、依帕司他单药、索拉非尼单药、联合治疗组分别为(238.940±39.813)mm^3、(124.991±84.670)mm^3、(-26.111±11.518)mm^3、(-54.072±17.673)mm^3,F=37.048,P<0.001;瘤体质量分别为(0.273±0.140)g、(0.158±0.078)g、(0.079±0.054)g、(0.045±0.024)g,F=16.594,P<0.001,差异均有统计学意义。给药组与对照组肿瘤平均质量比值分别为100%、57.9%、28.9%、16.5%。Ki-67阳性率分别为23.295%±6.218%、13.503%±3.392%、7.325%±2.257%、4.664%±1.189%,(χ^2=822.203,P<0.001),差异有统计学意义。依帕司他单药组治疗前后瘤体体积差值(t=-3.579,P=0.002)、Ki-67阳性率比较(t=-10.003,P<0.001)明显低于对照组,差异均有统计学意义。联合治疗组治疗前后瘤体体积差值(t=2.056,P=0.025)、瘤体质量(t=2.101,P=0.043)、Ki-67阳性率(t=-2.850,P=0.005)明显低于索拉非尼单药组,差异均有统计学意义。给药组与对照组相比,裸鼠体质量均有一定下降,但依帕司他组与对照组(t=-1.599,P=0.262)、联合治疗与索拉非尼组(t=-0.051,P=0.96)相比,体质量下降均无统计学意义。结论AKR1B10抑制剂可增强索拉非尼对肝癌异种移植瘤的抑制作用。 展开更多
关键词 肝细胞 肝癌异种移植瘤 醛酮还原酶1B10 依帕司他 索拉非尼 联合治疗
原发性甲状腺鳞癌患者生存率影响因素的研究进展 预览
5
作者 林史昂 张月飞 +1 位作者 罗国庆 何若云 《中国当代医药》 2019年第7期17-20,共4页
原发性甲状腺鳞状细胞癌是一种罕见的疾病,目前并没有相应统一的标准治疗方案。原发性甲状腺鳞状细胞癌患者的生存率不尽相同,并且不尽如人意。影响原发性甲状腺鳞状细胞癌患者生存率的因素成为近年来越来越多的学者关注的热点。本文总... 原发性甲状腺鳞状细胞癌是一种罕见的疾病,目前并没有相应统一的标准治疗方案。原发性甲状腺鳞状细胞癌患者的生存率不尽相同,并且不尽如人意。影响原发性甲状腺鳞状细胞癌患者生存率的因素成为近年来越来越多的学者关注的热点。本文总结近年来该领域重要文献的研究结果,探讨原发性甲状腺鳞状细胞癌患者生存率的影响因素。 展开更多
关键词 甲状腺肿瘤 鳞状细胞癌 原发性
在线阅读 下载PDF
Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure 预览
6
作者 Brianna J Shinn Aaron Martin +5 位作者 Robert M Coben Mitchell I Conn Jorge Prieto Howard Kroop Anthony J DiMarino Hie-Won Hann 《世界肝病学杂志:英文版(电子版)》 2019年第1期65-73,共9页
Hepatitis B virus (HBV) is one of the most significant hepatocarcinogens. The ultimate goal of anti-HBV treatment is to prevent the development of hepatocellular carcinoma (HCC). During the last two decades, with the ... Hepatitis B virus (HBV) is one of the most significant hepatocarcinogens. The ultimate goal of anti-HBV treatment is to prevent the development of hepatocellular carcinoma (HCC). During the last two decades, with the use of currently available anti-HBV therapies (lamivudine, entecavir and tenofovir disoproxil fumatate), there has been a decrease in the incidence of HBVassociated HCC (HBV-HCC). Furthermore, several studies have demonstrated a reduction in recurrent or new HCC development after initial HCC tumor ablation. However, during an observation period spanning 10 to 20 years, several case reports have demonstrated the development of new, subsequent new and recurrent HCC even in patients with undetectable serum HBV DNA. The persistent risk for HCC is attributed to the presence of covalently closed circular DNA (cccDNA) in the hepatocyte nucleus which continues to work as a template for HBV replication. While a functional cure (loss of hepatitis B surface antigen and undetectable viral DNA) can be attained with nucleos(t)ide analogues, these therapies do not eliminate cccDNA. Of utmost importance is successful eradication of the transcriptionally active HBV cccDNA from hepatocyte nuclei which would be considered a complete cure. The unpredictable nature of HCC development in patients with chronic HBV infection shows the need for a complete cure. Continued support and encouragement for research efforts aimed at developing curative therapies is imperative. The aims of this minireview are to highlight these observations and emphasize the need for a cure for HBV. 展开更多
关键词 Hepatitis B HEPATOCELLULAR CARCINOMA Antiviral THERAPY PERSISTENT RISK for HEPATOCELLULAR CARCINOMA Tumor ablation
在线阅读 免费下载
泪囊原发性恶性肿瘤22例临床病理学分析
7
作者 蒋永强 王彬 +1 位作者 李晓华 卜战云 《中华眼外伤职业眼病杂志》 2019年第2期81-84,共4页
目的分析泪囊原发性恶性肿瘤的临床病理学特点。方法对2014年1月至2017年12月22例(22只眼)泪囊恶性肿瘤的临床及病理资料进行回顾性分析。结果手术摘除肿瘤后,行病理学检查其性质。恶性上皮源性肿瘤12例(54. 5%):其中鳞状细胞癌5例(41.... 目的分析泪囊原发性恶性肿瘤的临床病理学特点。方法对2014年1月至2017年12月22例(22只眼)泪囊恶性肿瘤的临床及病理资料进行回顾性分析。结果手术摘除肿瘤后,行病理学检查其性质。恶性上皮源性肿瘤12例(54. 5%):其中鳞状细胞癌5例(41.7%)、内翻性乳头状瘤恶变2例(16.7%)、未分化癌2例(16.7%)、基底细胞癌1例(8.33%)及腺癌1例(8.33%)及腺样囊性癌1例(8.33%)。恶性非上皮源性肿瘤10例(45.5%):其中黏膜相关性B细胞淋巴瘤5例(50.00%)、恶性黑色素瘤3例(30.00%)、泪囊血管平滑肌肉瘤1例(10.00%)和隆突性纤维肉瘤1例(10.00%)。结论泪囊恶性肿瘤多为鳞状细胞癌、黏膜相关性B细胞淋巴瘤和恶性黑色素瘤。 展开更多
关键词 泪器疾病 鳞状细胞 基底细胞 黏膜相关淋巴样组织
WT1基因在NSCLC中的表达及其临床意义
8
作者 曹强 杨扬 +2 位作者 许瑞彬 刘延风 任清泉 《实用肿瘤杂志》 CAS 2019年第1期23-26,共4页
目的探讨Wilms tumor gene 1(WT1)基因在非小细胞肺癌(non-small-cell lung cancer,NSCLC)中的表达及其临床意义。方法通过实时荧光定量PCR技术检测100例NSCLC组织石蜡标本及对照标本(40例癌旁组织和40例良性病变组织)中WT1基因的表达量... 目的探讨Wilms tumor gene 1(WT1)基因在非小细胞肺癌(non-small-cell lung cancer,NSCLC)中的表达及其临床意义。方法通过实时荧光定量PCR技术检测100例NSCLC组织石蜡标本及对照标本(40例癌旁组织和40例良性病变组织)中WT1基因的表达量,以对照组WT1相对表达量均值为比较标准,将癌组织WT1表达量分为高表达和低表达;分析WT1表达量与NSCLC患者临床特征、生存期之间的关系。结果与对照组组织比较,WT1基因在NSCLC组织中高表达[(4. 295±1. 477) vs (1. 001±0. 002),P <0. 01]。WT1基因表达在NSCLC患者病理类型[(4. 132±0. 576) vs (6. 118±0. 525)]、分化程度[(3. 973±0. 329) vs (5. 683±0. 383)]、TNM分期[(4. 829±0. 137) vs (5. 685±0. 473)]和淋巴结转移[(3. 165±0. 499) vs (5. 186±0. 618)]方面比较,差异均具有统计学意义(均P <0. 01)。WT1高表达患者(WT1表达≥1. 001)生存期缩短(43个月vs 59个月,P=0. 002)。结论WT1基因在NSCLC组织中高表达,且高表达能够促进NSCLC分化和转移,缩短患者生存期。 展开更多
关键词 非小细胞肺/病理学 非小细胞肺/遗传学 WT1蛋白质类/代谢 WT1蛋白质类/遗传学 基因表达 逆转录聚合酶链反应/方法 预后
Cancer risk in primary sclerosing cholangitis:Epidemiology,prevention,and surveillance strategies 预览
9
作者 Brian M Fung Keith D Lindor James H Tabibian 《世界胃肠病学杂志:英文版》 SCIE CAS 2019年第6期659-671,共13页
Primary sclerosing cholangitis(PSC)is a rare cholestatic liver disease characterized by progressive fibroinflammatory destruction of the intra-and/or extrahepatic biliary ducts.While its features and disease course ca... Primary sclerosing cholangitis(PSC)is a rare cholestatic liver disease characterized by progressive fibroinflammatory destruction of the intra-and/or extrahepatic biliary ducts.While its features and disease course can be variable,most patients with PSC have concurrent inflammatory bowel disease and will eventually develop liver cirrhosis and end-stage liver disease,with liver transplantation representing the only potentially curative option.Importantly,PSC is associated with a significantly increased risk of malignancy compared to the general population,mainly cholangiocarcinoma,gallbladder carcinoma,hepatocellular carcinoma,and colorectal cancer,with nearly 50%of deaths in patients with PSC being due to cancer.Therefore,robust surveillance strategies are needed,though uncertainty remains regarding how to best do so.In this review,we discuss the epidemiology,prevention,and surveillance of cancers in patients with PSC.Where evidence is limited,we present pragmatic approaches based on currently available data and expert opinion. 展开更多
关键词 BILE duct diseases CHOLANGIOCARCINOMA GALLBLADDER CARCINOMA Hepatocellular CARCINOMA Colorectal cancer CHEMOPROTECTION Inflammatory bowel disease
在线阅读 免费下载
胃肠道菌群与胃肠道恶性肿瘤关系研究
10
作者 陈建伟 李红霞 董秀山 《国际外科学杂志》 2019年第4期277-280,共4页
胃肠道菌群是由数量庞大且结构复杂的微生物组成,参与了营养物质的分解、消化与吸收过程,促进了机体免疫系统的发育、抑制病原菌的定植,影响着机体的健康和疾病的发生。近几年随着测序技术的进步,胃肠道菌群与胃肠道恶性肿瘤的关系成为... 胃肠道菌群是由数量庞大且结构复杂的微生物组成,参与了营养物质的分解、消化与吸收过程,促进了机体免疫系统的发育、抑制病原菌的定植,影响着机体的健康和疾病的发生。近几年随着测序技术的进步,胃肠道菌群与胃肠道恶性肿瘤的关系成为当前的一个研究热点。本文就胃肠道菌群致癌途径以及胃肠道菌群可能的致癌机制进行综述。 展开更多
关键词 免疫系统 胃肠道 胃肠道菌群
Clinical value of serum pepsinogen levels for the diagnosis of esophageal squamous cell carcinoma 预览
11
作者 D.J. Rivadeneira Hesheng Luo Jingyuan Tian 《肿瘤学与转化医学:英文版》 2019年第1期19-24,共6页
Objective Pepsinogens have been previously studied as markers of gastric atrophy. The objective of this study was to investigate the clinical significance of the serum levels of pepsinogen (PG) I and II, as well as th... Objective Pepsinogens have been previously studied as markers of gastric atrophy. The objective of this study was to investigate the clinical significance of the serum levels of pepsinogen (PG) I and II, as well as the pepsinogen I/II ratio (PGR) in the diagnosis of esophageal squamous cell carcinoma. Methods A retrospective data analysis of patients who underwent gastroscopy and PG examination in Renmin Hospital was performed. The subjects were grouped into cancer and healthy control groups, and the differences in the serum levels of PGI and PGII, as well as the PGRs were compared. The receiver operating curve and the area under the curve (AUC) were also compared between the groups. Results A total of 351 Chinese patients were enrolled in the study, 209 with esophageal squamous cell carcinoma and 142 healthy controls. Overall, the levels of PGI (P < 0.0001) and PGII (P = 0.0007), as well as the PGR (P = 0.007) of the cancer group were lower than those of the control group. Male subjects in the cancer group had lower PGI (P < 0.0001), PGII (P < 0.0001), and (P = 0.0138). The subjects < 65 years old in the cancer group showed lower PGI (P < 0.0001), PGII (P = 0.001), and PGR (P = 0.0087).Overall, these results show that the levels of PGI (AUC 0.64) and PGII (AUC 0.60) have a predictive ability for discriminating esophageal carcinoma. Moreover, in males < 65 years old, PGI (AUC 0.73) and PGII (AUC 0.69) also showed to have a predictive ability for discriminating esophageal carcinoma. Conclusion Serum PG levels in patients with esophageal squamous cell carcinoma, especially in males aged < 65 years old, are lower than those in healthy people. PGI and PGII are useful for screening esophageal squamous cell carcinoma. 展开更多
关键词 PEPSINOGEN ESOPHAGEAL SQUAMOUS cell carcinoma SCREENING
在线阅读 下载PDF
Ⅰ期非小细胞肺癌术后的预后分析 预览
12
作者 姚源山 华青旺 沈海波 《中国肿瘤外科杂志》 CAS 2019年第1期36-40,共5页
目的 探讨Ⅰ期肺癌术后复发转移的相关因素。方法收集2010年1月至2015年12月在宁波市第二医院接受手术治疗并定期复查的251例Ⅰ期肺癌患者病历资料,对术后复发转移因素进行分析。结果 251例患者中局部复发与远处转移47例,复发转移率18.... 目的 探讨Ⅰ期肺癌术后复发转移的相关因素。方法收集2010年1月至2015年12月在宁波市第二医院接受手术治疗并定期复查的251例Ⅰ期肺癌患者病历资料,对术后复发转移因素进行分析。结果 251例患者中局部复发与远处转移47例,复发转移率18.7%;中位随访时间43.1(9.5~97.2)个月。单因素分析显示不同性别、年龄、病理类型、分化程度、是否化疗、肿瘤最大径、胸膜侵犯及脉管癌栓的术后复发转移率差异无统计学意义( P >0.05),不同的清扫淋巴结个数(≤15个和>15个)以及不同的术前血清CEA浓度(>5 ng/ml和≤5 ng/ml)术后复发转移率差异有统计学意义( P <0.05)。多因素分析显示,清扫淋巴结≤15个及术前血清CEA 浓度>5 ng/ml为肺癌术后复发转移高危因素。结论术前血清CEA浓度>5 ng/ml及清扫淋巴结≤15个患者,术后应积极随访。 展开更多
关键词 肺肿瘤 非小细胞肺 早期 手术 复发 肿瘤转移
在线阅读 下载PDF
2-脱氧葡萄糖逆转非小细胞肺癌细胞对奥希替尼继发性耐药的作用及机制
13
作者 郝帅 卢从华 +5 位作者 林采余 陈恒屹 李力 王玉波 封明霞 何勇 《中华结核和呼吸杂志》 CAS CSCD 北大核心 2019年第3期198-205,共8页
目的探究2-脱氧葡萄糖(2-DG)逆转非小细胞肺癌细胞对奥希替尼继发性耐药的作用及机制。方法将非小细胞肺癌(NSCLC)细胞株H1975(购自美国国家细胞库)通过体外诱导法处理后建立奥希替尼继发性耐药肺癌细胞株H1975-OR,用3-(4,5-二甲基噻唑-... 目的探究2-脱氧葡萄糖(2-DG)逆转非小细胞肺癌细胞对奥希替尼继发性耐药的作用及机制。方法将非小细胞肺癌(NSCLC)细胞株H1975(购自美国国家细胞库)通过体外诱导法处理后建立奥希替尼继发性耐药肺癌细胞株H1975-OR,用3-(4,5-二甲基噻唑-2)-2,5-二苯基四氮唑溴盐(MTT)法、克隆形成实验、Ki67蛋白荧光染色、凋亡通路相关蛋白表达水平检测,评估细胞株H1975-OR对奥希替尼的耐药性;通过测定细胞株H1975和H1975-OR培养基上清液中乳酸含量确定细胞糖酵解水平;Western blot法检测糖酵解关键酶(己糖激酶2、葡萄糖转运子1、磷酸化丙酮酸激酶M2亚型)及凋亡相关蛋白(B淋巴细胞瘤-2、Bcl-2蛋白相互作用的细胞死亡调解子)的表达;分为空白对照、2-脱氧葡萄糖(4 mmol/L)单药处理、奥希替尼(3μmol/L)单药处理、2-脱氧葡萄糖(4 mmol/L)+奥希替尼(3μmol/L)联合处理组,用流式细胞分析仪检测药物处理后的细胞凋亡率,评估药物的促凋亡能力。采用SPSS 16.0统计软件,用独立t检验对结果进行统计分析。结果奥希替尼敏感细胞株H1975比奥希替尼继发性耐药细胞株H1975-OR的糖酵解水平低[乳酸产生量分别为(21.0±0.9)和(26.5±2.8)mmol/(L×10^4cells),P<0.05];细胞株H1975-OR经4 mmol/L的2-脱氧葡萄糖处理后可逆转其对奥希替尼的继发性耐药,对奥希替尼的IC50值由(7.0±1.9)μmol/L降至(1.4±0.1)μmol/L,接近敏感细胞株H1975对奥希替尼的IC50值(1.0±0.2)μmol/L;细胞株H1975-OR经2-脱氧葡萄糖+奥希替尼联合处理后细胞凋亡率为(26.7±2.4)%,显著高于对照组的(5.1±0.7)%、2-脱氧葡萄糖单药处理组的(6.1±2.5)%和奥希替尼单药处理组的(11.4±2.7)%(均P<0.05);细胞株H1975-OR经2-脱氧葡萄糖+奥希替尼联合处理后,BIM蛋白表达为(177.8±28.1)%,显著高于对照组的(100.0±0)%(P<0.05);Bcl-2蛋白表达为(24.6±5.2)%,显著低于对照组的(100±0)%(P<0.05)。结论2-脱氧葡萄糖可以� 展开更多
关键词 非小细胞肺 脱氧葡萄糖 糖酵解
术前CA19-9联合血小板和淋巴细胞比值预测胰腺导管内乳头状黏液性肿瘤癌变风险的价值分析
14
作者 李剑昂 韩序 +7 位作者 方圆 张磊 楼文晖 许雪峰 吴文川 匡天涛 王单松 戎叶飞 《中华外科杂志》 CAS CSCD 北大核心 2019年第3期170-175,共6页
目的探讨术前预测胰腺导管内乳头状黏液性肿瘤(IPMN)癌变的相关因素。方法采用回顾性病例队列研究。选择2005年1月至2014年12月于复旦大学附属中山医院胰腺外科进行手术治疗,并经术后病理学检查证实为胰腺IPMN的79例患者资料。男性46例... 目的探讨术前预测胰腺导管内乳头状黏液性肿瘤(IPMN)癌变的相关因素。方法采用回顾性病例队列研究。选择2005年1月至2014年12月于复旦大学附属中山医院胰腺外科进行手术治疗,并经术后病理学检查证实为胰腺IPMN的79例患者资料。男性46例,女性33例;年龄为(62.9±8.9)岁(范围:37~82岁)。肿瘤部位:胰头部56例,胰体尾部22例,全胰1例。手术方式:胰十二指肠切除术51例,胰体尾切除术22例,节段胰腺切除术4例,全胰腺切除术2例。根据肿瘤的组织病理学特征,将IPMN分为非浸润性病变和浸润癌,其中浸润癌32例,非浸润性病变47例。分别采用t检验和χ^2检验对非浸润性IPMN和浸润癌IPMN的各项术前指标进行单因素分析,并对单因素分析结果中有统计学意义的指标进行多因素分析。结果单因素分析结果显示,肿瘤大小(P=0.022)、癌胚抗原(P=0.012)、CA19-9(P=0.011)、淋巴细胞数目(P=0.034)、中性粒细胞与淋巴细胞比值(P=0.010)和血小板与淋巴细胞比值(PLR)(P=0.004)是具有统计学意义的预测因素。多因素分析结果显示,CA19-9(P=0.012)和PLR(P=0.025)是预测IPMN发生癌变的独立因素。CA19-9和PLR的联合预测因素的曲线下面积(0.864)大于CA19-9(0.806)和PLR(0.685),同时联合预测因素的各真实性评价指标均优于两者单独应用。结论CA19-9和PLR是能够预测IPMN癌变风险的独立因素,而CA19-9和PLR联合应用较两者单独应用效能好。 展开更多
关键词 胰腺肿瘤 导管内 非浸润性 浸润癌 糖抗原19-9 血小板与淋巴细胞比值
Clinicohistopathological implications of phosphoserine 9 glycogen synthase kinase-3β/β-catenin in urinary bladder cancer patients 预览
15
作者 Niharika Maurya Rinni Singh +4 位作者 Apul Goel Atin Singhai Uday Pratap Singh Vinita Agrawal Minal Garg 《世界临床肿瘤学杂志(英文版)》 2019年第4期166-182,共17页
BACKGROUND Aberrant activation of phosphorylated form of glycogen synthase kinase-3β[pS9GSK-3β(Serine 9 phosphorylation)] is known to trigger Wnt/β-catenin signal cascade but its clinicohistopathological implicatio... BACKGROUND Aberrant activation of phosphorylated form of glycogen synthase kinase-3β[pS9GSK-3β(Serine 9 phosphorylation)] is known to trigger Wnt/β-catenin signal cascade but its clinicohistopathological implications in bladder carcinogenesis remain unknown. AIM To investigate the diagnostic and prognostic relevance of expressions of pS9GSK- 3β,β-catenin and its target genes in the pathobiology of bladder cancer. METHODS Bladder tumor tissues from ninety patients were analyzed for quantitative expression and cellular localization of pS9GSK-3β by immunohistochemical (IHC) staining. Real time-quantitative polymerase chain reaction and IHC were done to check the expression of β-catenin, Cyclin D1, Snail and Slug at transcriptome and protein level respectively. Clinicohistopathological variables were obtained from histology reports, follow up and OPD visits of patients. Expressions of the markers were statistically correlated with these variables to determine their significance in clinical setting. Results were analysed using SPSS 20.0 software.RESULTS Aberrant (low or no membranous/high nuclear/high cytoplasmic) expression of pS9GSK-3β was noted in 51% patients and found to be significantly associated with tumor stage and tumor grade (P = 0.01 and 0.04;Mann Whitney U test). Thirty one percent tumors exhibited aberrant co-expression of pS9GSK-3β and β–catenin proteins and showed strong statistical association with tumor stage, tumor type, smoking/tobacco chewing status (P = 0.01, 0.02 and 0.04, Mann- Whitney U test) and shorter overall survival probabilities of patients (P = 0.02;Kaplan Meier test). Nuclear immunostaining of Cyclin D1 in tumors with altered pS9GSK-3β/β–catenin showed relevance with tumor stage, grade and type. CONCLUSION β–catenin and pS9GSK-3β proteins are identified as markers of diagnostic/prognostic significance in disease pathogenesis. Observed histopathological association of Cyclin D1 identifies it as marker of potential relevance in tumors with altered pS9GSK-3β/β-cateni 展开更多
关键词 PATHOBIOLOGY Target GENES Tumor stage and grade Wnt/β–catenin signal CASCADE UROTHELIAL carcinoma of BLADDER
在线阅读 免费下载
丙氨酸-乙醛酸转氨酶2类似物1对人肝癌97H和HCCLM3细胞增殖、凋亡和周期的影响
16
作者 李志坚 贺德 +2 位作者 马广念 李蒙 邓思远 《中华实验外科杂志》 CAS CSCD 北大核心 2019年第2期248-250,共3页
目的 观察丙氨酸-乙醛酸转氨酶2类似物1(AGXT2L1)对肝癌细胞增殖、凋亡和周期的调控作用。方法 实时定量反转录聚合酶链反应(RT-qPCR)检测肝癌细胞株97H、HCCLM3和正常肝细胞株LO2中AGXT2L1的表达水平;设计并构建AGXT2L1的靶向siRNA,将A... 目的 观察丙氨酸-乙醛酸转氨酶2类似物1(AGXT2L1)对肝癌细胞增殖、凋亡和周期的调控作用。方法 实时定量反转录聚合酶链反应(RT-qPCR)检测肝癌细胞株97H、HCCLM3和正常肝细胞株LO2中AGXT2L1的表达水平;设计并构建AGXT2L1的靶向siRNA,将AGXT2L1-siRNA转染97H和HCCLM3细胞株构建AGXT2L1靶向敲低组和阴性对照组,通过RT-qPCR验证敲低效果;采用细胞计数试剂盒(CCK-8)实验检测各组细胞在0、12、24、48、72、96 h的增殖能力;采用流式细胞周期实验检测各组细胞在G1、S、G2期的分布情况;采用原位缺口末端标记法(TUNEL)实验检测各组细胞的凋亡率。结果 AGXT2L1在肝癌97H和HCCLM3细胞中相对表达高于正常肝细胞LO2(1 350.04±91.36、1 710.64±92.34,t97H=25.574,P<0.01;tHCCLM3=32.068,P<0.01)。转染AGXT2L1-siRNA后,对比对照组及空白组,肝癌97H和HCCLM3细胞内AGXT2L1相对表达量明显降低(0.19±0.04比1.10±0.04,t97H=-28.722,P<0.01;0.20±0.01比0.93±0.09,tHCCLM3=-13.887,P<0.01)。CCK-8实验结果显示,敲低AGXT2L1后,97H和HCCLM3细胞的增殖率明显下降(0.71±0.01比0.95±0.12,t97H=-31.243,P<0.01;0.67±0.13比0.87±0.17,tHCCLM3=-17.083,P<0.01),差异有统计学意义。细胞周期实验结果显示,干扰AGXT2L1表达后,S期细胞比例低于对照组[(13.45±1.20)%比(18.73±0.28)%,t97H=-7.451,P<0.01;(15.26±0.52)%比(20.45±1.08)%,tHCCLM3=-7.483,P<0.01];G2期细胞比例低于对照组[(16.90±0.54)%比(19.99±0.54)%,t97H=-6.992,P<0.01;(16.23±0.28)%比(23.36±0.39)%,tHCCLM3=-25.720,P<0.01],抑制细胞从G1期向S期转变,抑制肝癌细胞增殖。细胞凋亡实验显示:干扰AGXT2L1表达后,97H和HCCLM3细胞凋亡率明显升高[(13.06±1.86)%比(1.06±0.75)%,t97H=14.673,P<0.01;(14.41±2.21)%比(0.80±0.32)%,tHCCLM3=14.947,P<0.01],差异有统计学意义。结论 敲低AGXT2L1的表达抑制肝癌97H和HCCLM3细胞株增殖,促进细胞凋亡。 展开更多
关键词 肝细胞 丙氨酸-乙醛酸转氨酶2类似物1 增殖 脱噬作用
低氧诱导的miR-210在非小细胞肺癌中预后价值的探讨
17
作者 陈瑞琳 武润苗 +1 位作者 吴桦 杨淑梅 《国际呼吸杂志》 2019年第2期101-106,共6页
目的调查microRNA-210(miR-210)在非小细胞肺癌(NSCLC)患者中的预后价值。方法本研究使用逆转录-聚合酶链反应检测了从2011年1月到2012年3月在陕西省人民医院胸外科接受手术治疗的NSCLC患者的新鲜组织标本中miR-210表达,统计分析miR-21... 目的调查microRNA-210(miR-210)在非小细胞肺癌(NSCLC)患者中的预后价值。方法本研究使用逆转录-聚合酶链反应检测了从2011年1月到2012年3月在陕西省人民医院胸外科接受手术治疗的NSCLC患者的新鲜组织标本中miR-210表达,统计分析miR-210表达与全组患者、肺腺癌和鳞状细胞癌之间的临床因素之间的关系;分析miR-210表达差异和全部患者及其肺腺癌患者的无瘤生存率和总生存率之间的关系。结果在NSCLC中,miR-210高表达患者比miR-210低表达患者的无瘤生存率更低(χ^2=8.119,P<0.01),总生存率更短(χ^2=7.914,P<0.01);在肺腺癌中,miR-210高表达组患者比miR-210低表达组的无瘤生存率更低(RR=2.181,P<0.01),总生存率更短(RR=1.978,P<0.01);miR-210表达与病理分期、淋巴结转移和疾病复发(P<0.05)显著性相关。Cox多因素分析显示,miR-210表达为总生存率的独立预后因素(RR=1.978,P<0.05)。结论miR-210在NSCLC患者,高表达特别是与肺腺癌的患者预后显著相关。miR-210可能为肺腺癌患者预后的生物标志物。 展开更多
关键词 非小细胞肺 MIR-210 肺腺癌
肿瘤标志物变化水平对于TACE治疗肝细胞癌的价值 预览
18
作者 苏国庆 王凯冰 +2 位作者 金书强 李映辰 白彬 《中国介入影像与治疗学》 北大核心 2019年第1期57-60,共4页
肝细胞癌(HCC)是最常见的恶性肿瘤之一。目前TACE是HCC的首选姑息性治疗方法。近年在蛋白质组、mRNA组中发现了一系列HCC代谢产物。本文对HCC常见及目前热点研究的肿瘤标志物对于TACE治疗的价值进行综述。
关键词 肝细胞 肝动脉 栓塞 治疗性 肿瘤标志物
在线阅读 下载PDF
CK2抑制剂CX4945对肺癌A549/DDP细胞顺铂耐药性的逆转作用
19
作者 金承基 宋萍 +2 位作者 郑金旭 孙金玲 徐莉莉 《肿瘤》 CAS CSCD 北大核心 2019年第1期10-18,40共10页
目的 :探讨蛋白激酶CK2(casein kinase 2,曾称酪蛋白激酶Ⅱ)抑制剂CX4945对顺铂(cisplatin,DDP)耐药性肺癌A549/DDP细胞生长活性的影响及其可能的作用机制。方法 :CCK-8法检测肺癌A549细胞及其耐药性A549/DDP细胞的DDP半数抑制浓度(half... 目的 :探讨蛋白激酶CK2(casein kinase 2,曾称酪蛋白激酶Ⅱ)抑制剂CX4945对顺铂(cisplatin,DDP)耐药性肺癌A549/DDP细胞生长活性的影响及其可能的作用机制。方法 :CCK-8法检测肺癌A549细胞及其耐药性A549/DDP细胞的DDP半数抑制浓度(half maximal inhibitory concentration,IC50),以及抑制剂CX4945对A549/DDP细胞耐药性的影响。蛋白质印迹法检测A549及A549/DDP细胞在DDP干预前后Wnt信号通路相关蛋白(CK2α、β-catenin和cyclin D1)、耐药相关蛋白[多药耐药相关蛋白1(multidrug resistance-associated protein 1,MRP1)和肺耐药相关蛋白(lung resistance-related protein,LRP)]和凋亡相关蛋白[剪切型半胱天冬酶-3(cleaved caspase-3,c-caspase-3)]的表达变化。将A549/DDP细胞分为未处理对照组、CX4945组、DDP组及CX4945+DDP组,各组药物处理后,采用蛋白质印迹法和FCM法分别检测Wnt信号通路、耐药及凋亡相关蛋白的表达以及细胞凋亡情况。结果:DDP对A549/DDP细胞的IC50值是A549细胞的4.59倍,并在CX4945预处理后A549/DDP细胞耐药性明显降低(P <0.001)。与A549细胞相比,A549/DDP细胞中CK2α、β-catenin、cyclin D1、MRP1和LRP蛋白的表达水平明显较高,并在DDP处理后进一步升高(P值均<0.001);然而A549细胞中,DDP处理后CK2α、β-catenin和cyclin D1蛋白表达水平明显降低(P值均<0.01),而MRP1和LRP蛋白表达则无明显变化(P值均>0.05)。与未处理对照组和DDP组相比,CX4945组和CX4945+DDP组的A549/DDP细胞中β-catenin、cyclin D1、MRP1和LRP蛋白表达水平均明显降低(P值均<0.01)。此外,CX4945+DDP组的A549/DDP细胞凋亡率和c-caspase-3表达水平均较未处理对照组和DDP组明显升高(P值均<0.001)。结论 :CK2抑制剂CX4945可通过抑制Wnt通路,降低耐药相关蛋白的表达,从而逆转肺癌A549/DDP细胞的顺铂耐药性。 展开更多
关键词 非小细胞肺 抗药性 肿瘤 WNT信号通路 顺铂 酪蛋白激酶Ⅱ CX4945
肝Ⅷ段大肝癌手术切除安全性及疗效分析 预览
20
作者 沈伟峰 蔡文昌 +4 位作者 耿利 隋承军 戴炳华 陆炯炯 杨甲梅 《中华肝脏外科手术学电子杂志》 CAS 2019年第2期122-126,共5页
目的探讨肝Ⅷ段大肝癌手术切除治疗的安全性和疗效。方法回顾性分析2008年1月至2012年12月在东方肝胆外科医院行肝Ⅷ段大肝癌切除的17例患者临床资料。其中男15例,女2例;年龄30~62岁,中位年龄49岁。患者均签署知情同意书,符合医学伦理... 目的探讨肝Ⅷ段大肝癌手术切除治疗的安全性和疗效。方法回顾性分析2008年1月至2012年12月在东方肝胆外科医院行肝Ⅷ段大肝癌切除的17例患者临床资料。其中男15例,女2例;年龄30~62岁,中位年龄49岁。患者均签署知情同意书,符合医学伦理学规定。术中采用低中心静脉压,合理应用各种血流阻断法,控制肝静脉和下腔静脉大出血,以完整切除肿瘤为原则。生存分析采用Kaplan-Meier法和Log-rank检验。结果17例患者均顺利完成手术,手术时间中位数133(80~190)min,术中出血量150(50~800)ml。输血3例,分别输血600、800、600ml。无围手术期死亡。术后9例出现并发症,其中胸腔积液7例,肺不张1例,腹腔积液+胸腔积液1例,无术中大出血、空气栓塞等严重并发症发生。16例术后行辅助性TACE治疗。患者无瘤生存时间12(1~116)个月,总体生存时间30(12~116)个月;1、3、5年无瘤生存率分别为58.8%、40.3%、30.3%,1、3、5年总体生存率分别为100.0%、48.1%、41.3%。结论肝切除仍是肝Ⅷ段大肝癌首选治疗方案,手术以完整切除肿瘤为主要目标,可获得良好疗效。术中采用多种措施控制出血,保护主要管道结构,避免损伤肝静脉和下腔静脉,预防空气栓塞,妥善处理好肝脏创面,可保证手术安全。 展开更多
关键词 肝细胞 肝切除术 手术后并发症 预后
在线阅读 下载PDF
上一页 1 2 250 下一页 到第
使用帮助 返回顶部 意见反馈